AI Article Synopsis
- A study in India assessed bortezomib (BZB) and reduced doses of cytarabine in treating children with relapsed acute lymphoblastic leukemia (rALL), involving 55 participants.
- Out of those treated, 88% achieved second remission and a significant number showed low minimal residual disease after induction therapy.
- The results showed promising one-year survival rates, with 74.7% event-free survival and 79.6% overall survival in the group receiving treatment.
Article Abstract
The feasibility of bortezomib (BZB) in induction and reduced cytarabine doses in intensification was evaluated in children with relapsed acute lymphoblastic leukaemia (rALL) at a single centre in India. Of 55 children with rALL, 23 received supportive care and 7 refused treatment, with a median survival of 2 (interquartile range 1-6) months. Twenty-two (88%) of 25 children who were treated achieved second remission and 9 (69%) of 13 had end-of-induction minimal residual disease of <10 . The lower cytarabine dose was associated with decreased hospitalisation. One-year event-free and overall survival for the treated group was 74·7% (95% confidence interval 52-88) and 79·6% (58-91) respectively.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785345 | PMC |
| http://dx.doi.org/10.1111/bjh.16005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!